期刊文献+

ELISPOT及ELISA鉴别HBV感染免疫状态的研究 被引量:1

Study on immune status of patients with HBV infection identified by ELISPOT and ELISA
原文传递
导出
摘要 目的比较酶联免疫斑点法(ELISPOT)、酶联免疫吸附试验(ELISA)鉴别乙型肝炎病毒(HBV)感染免疫状态。方法临床诊断的慢性HBV感染者免疫清除期、免疫耐受期患者各16例,常规分离外周血单个核细胞(PBMC),体外用HBcAg或培养液刺激,分别用ELISPOT及ELISA方法,检测两组患者PBMC分泌的r-干扰素(INFr)。结果用ELISA方法,两组患者PBMC受HBcAg刺激分泌IFNr,分别为(655.25士3.80)、(578.37±7.73)ng/L,阳性率分别为68.81%、12.50%,差异有统计学意义(P<0.01);用ELISPOT方法,两组患者PBMC受HBcAg刺激分泌IFNr,阳性率分别为87.50%、0,二者差异有统计学意义(P<0.01)。结论免疫清除期、免疫耐受期HBV感染者,PBMC对HBcAg刺激的免疫反应不同,鉴别二者,ELISPOT优于ELISA。 OBJECTIVE To compare the immune status of patients with HBV infection by enzyme link immune spot(ELISPOT)and enzyme-linked immunosorbent assay(ELISA).METHODS A total of 32 patients with chronic HBV infection were selected,16 patients in clearance period and 16 patients in tolerance period were included.The peripheral blood mononuclear cells(PBMC) from the patients were isolated by routine method,which were stimulated with HHBcAg in vitro or media in vitro.The interferon-r(IFNr) produced by PBMC were measured by the method of ELISPOT and ELISA.RESULTS By the means of ELISA,the IFNr produced by PBMC under the stimulation of HBcAg of the two groups of patients were(655.25士3.80 ng/L and(578.37±7.73) ng/L,the positive rates were 68.81% and 12.50%,respectively,the difference was statistically significant(P〈0.01);by the means of ELISPOT method,the positive rates of IFNr produced by PBMC under the stimulation of HBcAg were 87.50% and 0,respectively,the difference was statistically significant(P〈0.01).CONCLUSION For the patients with HBV infections during immune serum clearance period and immune tolerance period,PBMC has different response to the immune status under the stimulation of HBcAg,ELISPOT is superior to ELISA in differentiating the two.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2012年第11期2265-2267,共3页 Chinese Journal of Nosocomiology
基金 海南省自然基金(200831) 海南省卫生厅项目(200816)
关键词 酶联免疫斑点法 酶联免疫吸附试验 乙型肝炎病毒感染者 R-干扰素 Enzyme linked immune spot Enzyme-linked immunosorbent assay HBV carrier Interferon-r
  • 相关文献

参考文献10

  • 1Feng B, Wei L, Chen M,et al. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudinetreated patients with chronic hepatitis B[J]. Microbiological research, 2008,163 (4): 541-8.
  • 2Papatheodoridis GV,Chrysanthos N,Hadziyannis E,etal. Longi- tudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection[J]. Journal of viral hepatitis, 2008,15 (6) 593-8.
  • 3Yang PL, Althage A,Chung J,et al. Immune effectors required for hepatitis B virus clearance[J]. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107 (2) ,663-7.
  • 4施理,张宜俊,易学瑞,刘树人.小鼠免疫接种乙型肝炎病毒表面S疫苗引起的细胞毒T淋巴细胞反应[J].中华医院感染学杂志,2003,13(7):612-615. 被引量:6
  • 5Schumann A,Fiedler M, Dahmen U, et al. Cellular and humoral immune response to a third generation hepatitis B vaccine[J]. Journal of viral hepatitis,2007,14(8) : 592-598.
  • 6Yang SH,Lee CG,Park SH,et al. Correlation of antiviral Tcell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study[J]. Gene thera- py,2006,13(14) : 1110-1117.
  • 7Chichester JA, Feitelson MA,Calkins CE. Transient inhibition of Thl type cytokine production by CD4 T cells in hepatitis B core antigen immunized mice is mediated by regulatory T cells[J]. Immunology, 2006,118(4) : 438-448.
  • 8Li H,Zhou M, Han J,etal. Generation of murine CTL by a hepatitis B virus specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments[J]. The Journal of Immunology, 2005,174(1) : 195-204.
  • 9Eishiro Mizukoshi, Marc Ghany, Jay H, et al. Cellular Im-mune Responses to the Hepatitis B Virus polymerase[J]. The Journal of Immunology, 2004,173(9) : 5863-5871.
  • 10Chen W, Zhang Z, Shi M,et al. Activated plasmaeytoid dendritic cells act synergistically with hepatitis B core antigenpulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response[J]. Clin Immunoi,2008,129(2) :295-303.

二级参考文献16

  • 1Wright TL, Lau JYN. Clinical aspects of hepatitis B virus infection[J]. Lancet, 1993, 342: 1340-1344.
  • 2Wong DKH, Cheung AM, O'Rourke K, et al. Effect of al-pha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis [J]. Ann Intern Med,1993, 119: 312-323.
  • 3Lai C, Chien R, Leung N, et al. A one-year trial of lamivudine for chronic hepatitis B[J]. N Engl J Med, 1998, 339: 61-68.
  • 4Dienstag J, Perillo R, Sehiff E, et al. A preliminary trial of lamivudine for chronic hepatitis B infection[J]. N Engl J Med,1995, 333: 1657-1661.
  • 5Pol S, Nalpas B, Driss F, et al. Effieaey and limitations of a specifie immunotherapy in chronic hepatitis B[J]. J Hepatol,2001, 34: 917-921.
  • 6Mancini M, Hadchouel M, Tiollais P, et al. Induction of an-ti-hepatitis B surface antigen (HBsAg). Antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg[J]. J Med Virol, 1993, 39: 67-74.
  • 7Akbar SMF, Kurosa K, Tanimoto K, et al. Vaccine therapy for hepatitis B virus (HBV)-carriers: a study in routine HBV-carriers on dose, duration and prognosis [J]. Hepatology,1995, 22: 224A.
  • 8Hervas-Stubbs S, Lasarte J-J, Sarobe P, et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection[J]. J Hepatol, 1997, 27: 726-737.
  • 9Po S, Driss F, Michel ML, et al. Specific vaccine therapy in chronic hepatitis B infection[J]. Lancet, 1994, 344: 342.
  • 10Wen YM, Wu XH, Hu DC, et al. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy [J ].Lancet, 1995, 345: 1575-1576.

共引文献5

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部